This map shows the geographic impact of Borden Ec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Borden Ec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Borden Ec more than expected).
This network shows the impact of papers produced by Borden Ec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Borden Ec. The network helps show where Borden Ec may publish in the future.
Co-authorship network of co-authors of Borden Ec
This figure shows the co-authorship network connecting the top 25 collaborators of Borden Ec.
A scholar is included among the top collaborators of Borden Ec based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Borden Ec. Borden Ec is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Revel, Michel, et al.. (1997). Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.. PubMed. 3(1). 27–32.43 indexed citations
4.
Ec, Borden, et al.. (1994). Interleukin-6: a cytokine with potential diagnostic and therapeutic roles.. PubMed. 123(6). 824–9.60 indexed citations
5.
Ec, Borden, et al.. (1990). Cancer therapy with combinations of biological response modifiers and cytotoxics: an update.. PubMed. 2(7). 217–20.1 indexed citations
6.
Hong, Ruey‐Long, et al.. (1990). Biological and clinical effects of the oral immunomodulator 3,6-bis(2-piperidinoethoxy)acridine trihydrochloride in patients with malignancy.. PubMed. 9(1). 61–70.3 indexed citations
7.
Ec, Borden, et al.. (1990). Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma.. PubMed. 9(1). 108–11.7 indexed citations
8.
Ec, Borden, et al.. (1983). In vitro and in vivo effects of levamisole on monocyte chemotaxis in normal donors and patients with colorectal carcinoma.. PubMed. 2(2). 167–74.5 indexed citations
9.
Ec, Borden, et al.. (1983). Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.. PubMed. 2(5). 409–17.5 indexed citations
10.
Ec, Borden. (1983). Interferons: in pursuit of the promise.. PubMed. 132E. 287–96.4 indexed citations
11.
Ec, Borden. (1983). Interferons and cancer: how the promise is being kept.. PubMed. 5. 43–83.12 indexed citations
12.
Ec, Borden, et al.. (1983). Survey of human polyomavirus (JCV, BKV) infections in 139 patients with lung cancer, breast cancer, melanoma, or lymphoma.. PubMed. 105. 311–24.26 indexed citations
13.
Ec, Borden. (1974). Viruses and breast cancer: implications of mouse and human studies.. PubMed. 134(2). 66–76.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.